Please login to the form below

RoActemra

This page shows the latest RoActemra news and features for those working in and with pharma, biotech and healthcare.

CAR-Ts Kymriah and Yescarta step closer to approval in Europe

The EMA has laid out monitoring and mitigation strategies for these side effects, including the use of Roche’s RoActemra to treat CRS.

Latest news

Roche's Actemra/RoActemra receives new European approval

Roche's Actemra/RoActemra receives new European approval. EU regulators also pass the Swiss pharma firm’s Gazyvaro. ... As the first effective non-steroid therapy for GCA, Actemra/RoActemra has the potential to fundamentally change how this condition
Ocrevus off to a flying start as Roche raises 2017 forecasts

Perjeta (pertuzumab) for breast cancer continued to grow - rising 17% to 1.07bn francs - and immunotherapy Actemra/RoActemra (tocilizumab) also put in a good showing, rising 13% to 922m francs thanks
Sanofi/Regeneron bag first approval for Actemra rival sarilumab

Sarilumab is a fully human monoclonal antibody that binds specifically to both soluble and membrane-bound IL-6 receptors, and is the first direct competitor to Roche's Actemra/RoActemra (tocilizumab)
Manufacturing issues scupper Sanofi's sarilumab launch plans

Any delay to the programme is however a blow to Sanofi and Regeneron, which are playing catch-up against the only marketed IL-6 inhibitor - Roche's Actemra/RoActemra (tocilizumab) - while
Roche snags pair of FDA breakthrough designations

Meanwhile, Roche's interleukin-6 inhibitor RoActemra/Actemra (tocilizumab) picked up a BTD for giant cell arteritis, a chronic and potentially life-threatening autoimmune condition in which serious inflammation is seen

More from news
Approximately 5 fully matching, plus 27 partially matching documents found.

Latest Intelligence

Opening up innovation

If approved it will compete with the likes of Roche's RoActemra (tocilizumab). “

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Infographic: RA Perceptions

Partnership. An infographic highlights the key findings from the study. Biologic agents with novel mechanisms of action (such as Roche’ s RoActemra) are expected to outperform the overall EU biologics market
The Biosimilar Challenge

Herceptin, Avastin, Rituximab and Erbitux) and autoimmune disease (e.g. Humira, Enbrel, Remicade, MabThera and RoActemra to name a few).
The Biosimilar Challenge

Herceptin, Avastin, Rituximab and Erbitux) and autoimmune disease (e.g. Humira, Enbrel, Remicade, MabThera and RoActemra to name a few).
Infographic: RA Perceptions

Partnership. An infographic highlights the key findings from the study. Biologic agents with novel mechanisms of action (such as Roche’ s RoActemra) are expected to outperform the overall EU biologics market
Brand leaders in RA will lose market share, predict rheumatologists

market leaders Enbrel (etanercept) and Humira (adalimumab) will continue to lose market share to newer biologics such as RoActemra (tocilizumab), Orencia (abatacept) and Simponi (golimumab) and may experience strong competition from

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Project / Account Manager (Medical Education): Salary TBC

Associate Medical Director: Excellent PTO, bonus and 401k package

Production Manager – Healthcare Communications: DOE

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Account Director: £48, 000 - £60, 000

Medical Writer – Health Behaviour/ Patient Adherence Agency: Salary TBC

Scientific Director / Editorial Team Leader: Great salary and benefits

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Freelance Account Manager / Senior Account Manager - Medical Edu...: £300 per day

Associate Director, Market Access & HEOR – North-West: Negotiable

Programme Director, Healthcare PR, Highly competitive package: Highly Competitive package

Account Manager / Account Director: Competative

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Director, Market Access / HEOR - North-West: Negotiable

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Senior Medical Writer: Great salary and benefits

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

New Business Director - PR: Competitive Salary and benefits

Account Manager / Senior Account Manager: 35, 000-40, 000

Senior Account Manager- Central Oxford and Abingdon: Negotiable

Account Director: Excellent benefits

Account Manager, Healthcare Public Affairs: £32, 000 – £40, 000 benefits

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Associate Director: £75, 000-90, 000

Principal Health Economist - North-West: Negotiable

Subscribe to our email news alerts

PMHub

Add my company

PharmiWeb Solutions

PharmiWeb Solutions creates, delivers and manages digital solutions for the pharmaceutical and healthcare segment. From digital marketing, to patient education...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award: The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
Artificial Intelligence in Healthcare: Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer: Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...